Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: chances of recouping some value

May 20, 2021 7:33am

As we go from the merry-go-round to the roller-coaster

Pre-open indications: 2 BUYs, 5 SELLs and 1 Maintain SELL

Mentions: CRSP, GBT, EDIT, BLUE, CLLS, KDNY, NTLA, BSTG

My version of the morning’s “indications” is written on what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!

Dow futures are DOWN -0.40% (-134 points), S&P futures are DOWN -0.32% (-13 points) and NASDAQ futures are DOWN -0.24% (-32 points)

Pre-open futures were lower on Thursdays after sell-offs in speculative areas of the market

European stocks advanced bucking the trend seen in the U.S.

Asia-Pacific stocks were mixed, with data showing Japan’s exports surged in April.

Data Docket: U.S. weekly jobless claims

Henry’omics:

Wednesday's close logged a third straight day of losses as the cell and gene therapy sector collapsed again.

The S&P 500 slid 1.6% at its session low in the previous session but recouped most of the losses to close down just 0.3% as the bitcoin stabilized. The Dow finished the session about 160 points lower after plunging 580 points at one point. The Nasdaq ended the day flat, erasing a 1.7% drop.

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … thirty (30) to date … https://www.regmedinvestors.com/articles/11628

Wednesday’s evening’s recap: “panic and speculation devalue the sector. Fundamentals are trashed as sentiment crashes the cell and gene therapy sector yet again” … https://www.regmedinvestors.com/articles/11918

The Nasdaq closed DOWN -3.90 points (-0.03%);
The IBB closed down -0.92% and XBI closed down -1.75%;
Sector volume was LOW with 1 of the 7-upside having higher than the 3-month average volume with the volume of 2 of 27-downside having higher than the 3-month average volume;
The CBOE Volatility Index (VVIX: INDEX) was up +0.84 points or +3.94% at 22.18;
Wednesday’s percentage (%) of the 7-upside were +0.49% (VCEL) to +14.19% (BSTG) while the 27-downside ranges from -0.16% (ALNY) to -6.45% (BLCM);

Q2/21:

May: 4 positive and 9 negative closes

April: 11 negative and 10 positive closes

Q1/21:

March: 10 positive, 12 negative and 1 neutral closes
February: 9 positive, 10 negative closes and 1 holiday
January: 10 positive, 9 negative closes and 1 holiday

Companies in my headlights – It’s your decision; I provide an idea and context:

Biostage (BSTG): Questions continue … Maintaining Sell and still “pumping” the volume to keep price moving

Biostage (BSTG) closed up +$0.16 to $1.30 with 930 shares traded after Tuesday’s -$0.16 to $1.13 with 250 shares traded, Monday’s +$0.15 to $1.30 with 2,642 shares traded and last Friday’s flat with 54 shares traded.

Question#1: What is there to invest in, an IND a year old with NO clinical trial, NO management, barely any employees and huge overhead (buildings etc.) expense with WHAT capacity to finance?

Question#2: With only $1 million left in the “till” WHAT is the runway with a “spend” and “net cash in operations of $4 million during the year ended 12/ 31/20”. Don’t forget the PPP loan remaining as DEBT ($0.4 million).

MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.

The morning’s indications:

Maintaining SELL:

Chinook Therapeutics (KDNY) closed up +$0.68 to $16.87 after Tuesday’s -$0.53 to $16.19 after Monday’s +$1.87 to $16.72 with NO aftermarket indication.

BUY from SELL:

bluebird bio (BLUE) closed down -$1.24 to $29.43 after Tuesday’s +$0.76 to $30.67 and Monday’s -$0.41 to $29.91 with a positive +$0.51 or +1.73% aftermarket indications. Bristol Myers Squibb (NYSE: BMY) and BLUE announced new data and analyses from the pivotal KarMMa study evaluating Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell therapy. In the pivotal KarMMa study, 128 patients with relapsed or refractory multiple myeloma who had received at least three prior treatment regimens including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody were treated with Abecma at the target dose levels of 150 x 106 to 450 x 106 CAR-positive T cells. Patients had a median of six prior regimens (range: 3-16), with 84% (108/128) of patients being triple-class refractory.

Cellectis SA (CLLS) closed down -$0.56 to $15.52 after Wednesday’s $16.08, Tuesday’s $15.55 and last Monday’s $15.49 with a positive +0.33 or +2.13% pre-market indication,

Global Blood Therapeutics (GBT) closed down -$0.86 to $36.43 after Tuesday’s +$0.98 to $37.29 and Monday’s +$0.13 to $36.31 and has a positive +$0.27 or +0.74% pre-market indication.

Maintaining SELL:

Editas Medicine (EDIT) closed down -$0.46 to $33.11 after Tuesday’s +$0.46 to $33.57 and Monday’s $33.11 with a negative -$0.28 or -0,85% pre-market indications.

Intellia Therapeutics (NTLA) closed down -$1.88 to $64.48 after Tuesday’s $66.36 and Monday’s $66.69 with a negative -$0.48 or -0.74% aftermarket indication.

CRISPR Therapeutics (CRSP) closed down -$2.10 to $110.56 after Tuesday’s +$3.44 to $112.66 after Monday’s $109.22 and Friday’s $106.64 with a negative -$0.06 or -0.05% pre-market indication

The BOTTOM LINE: Yesterday showed-off with another bad session.

I am also back to my recurring question: where are the buyers coming from – the speculators?

Q1 earnings season is wrapping up – 30 of my 35 covered companies have reported.

I feel like a song from a broken record, “post earnings’ release, BUY some (few) short-term dips but, cautiously”.

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see some lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.